| |
|
|
|
Xtalks, online
2023 -5-25
As liquid biopsies become more commonplace, gaining wider US Food and Drug Administration (FDA) acceptance and even becoming standard of care in some instances, the technology is giving rise to important new questions. In this webinar, the featured speakers will explore the technique’s growing importance in early cancer detection and address common questions about its use.
The webinar will provide insights into developing an in vitro diagnostics test for early cancer detection with clinical, analytical and performance validation considerations. Attendees will learn how to approach single indication vs. multi-cancer screen indications, the advantages and disadvantages of lab-developed tests vs. premarket approval and the regulatory landscape for in vitro diagnostics. In addition, discover strategies for operationalizing large-scale clinical validation studies.
Join this webinar on in vitro diagnostics for early cancer detection for a discussion on the evolution and promise of liquid biopsy technology.
|
|
|
|
|
|
|
|
Organized by:
|
|
Xtalks |
|
|
Invited Speakers:
|
|
Matthew Nowland, Vice President, Regulatory Affairs, Premier Research Charlie Chrisawn, Executive Director, Program Strategy, In Vitro Diagnostics, Premier Research
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
2023 -5-25
|
|
|
|
|
|
|
|
Registration:
|
|
Free registration
|
|
|
E-mail:
|
|
ajuurinen@xtalks.com
|
|
|
|
|
|
|
|
|